bivalirudin (Angiomax)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Angiomax.

Indications

Contraindications

Pharmacokinetics

Adverse effects

Overdose

Mechanism of action

Clinical trials

More general terms

References

  1. Prescriber's Letter 8(2):11 2001
  2. 2.0 2.1 Stone GW et al, for the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17124018
    Bittl JA Accounting for Acuity N Engl J Med 2006, 355:2249 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17124024
  3. 3.0 3.1 3.2 Kastrati A et al. for the ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011 Nov 13 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22077909 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1109596
  4. 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  5. 5.0 5.1 Steg PG et al for the EUROMAX Investigators Bivalirudin Started during Emergency Transport for Primary PCI. N Engl J Med. October 30, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24171490 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1311096
    Mehta SR Balancing Thrombotic Events and Bleeding in Primary PCI. N Engl J Med. October 30, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24171491 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1312702
  6. 6.0 6.1 Deprecated Reference